Quirino Lai

Dr. Quirino Lai

Università La Sapienza, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
QLQuirino Lai
Quirino Lai
AAAlfonso W Avolio
Alfonso W Avolio
IGIvo Graziadei
Ivo Graziadei
GOGerd Otto
Gerd Otto
MRMassimo Rossi
Massimo Rossi
JLJan Lerut
Jan Lerut

30 September 2013 in Transplant International
Verified
Journal Article
Closed access
PDF file
QLQuirino Lai
Quirino Lai
ESEdward Castro Santa
Edward Castro Santa
JJJuan M. Rico Juri
Juan M. Rico Juri
RPRafael S. Pinheiro
Rafael S. Pinheiro
JLJan Lerut
Jan Lerut
There is increasing evidence that systemic inflammation markers like neutrophil (NLR) and platelet-to-lymphocyte ratios (PLR) may play a role in the outcome of hepatocellular cancer (HCC). Between January 1994 and March 2012, 181 patients with HCC were registered on the transplant waiting list: 35 (19.3%) patients dropped out during the waiting period and 146 (80.7%) patients underwent liver transplantation (LT). The median follow-up of this patient cohort was 4.2 years (IQR: 1.8-8.3). On c-statistics, the last NLR (AUROC = 67.4; P = 0.05) was the best predictor of dropout. The last PLR had an intermediate statistical ability (AUROC = 66.1; P = 0.07) to predict post-LT tumor recurrence. Patients with a NLR value >5.4 had poor 5-year intention-to-treat (ITT) survival rates (48.2 vs. 64.5%; P = 0.02). Conversely, PLR better stratified patients in relation to tumor-free survival (TFS) (80.7 vs. 91.6%; P = 0.02). NLR is a good predictor for the risk of dropout, while PLR is a good predictor for the risk of post-LT recurrence. Use of these markers, which are all available before LT, may represent an additional tool to refine the selection criteria of HCC liver recipients.

1 March 2017 in Transplantation
Verified
Journal Article
Closed access
QLQuirino Lai
Quirino Lai
EFEstelle Feys
Estelle Feys
VKVincent Karam
Vincent Karam
RARene Adam
Rene Adam
JKJurgen Klempnauer
Jurgen Klempnauer
JLJan P. Lerut
Jan P. Lerut
Hepatic epithelioid hemangioendothelioma (HEHE) is a rare vascular tumor which has an intermediate aggressive behavior. Although the value of liver transplantation (LT) is well established, its place in the management of HEHE is still unclear. The aim of this study is to confirm, based on a very large patient cohort, the value of LT in the management of HEHE and to identify risk factors for post-LT recurrence. The outcome of 149 transplant recipients with HEHE recorded in the European Liver Transplant Registry during the period November 1984 to May 2014 was analyzed. Median post-LT follow-up was 7.6 years (interquartile range, 2.8-14.4). Cox regression analysis showed that macrovascular invasion (hazard ratio [HR], 4.8; P Conclusions The analysis of this (largest in the world) HEHE adult liver recipient cohort clearly confirms the value of LT in the treatment of this rare disorder and also permits identification of patients at risk of posttransplant recurrence. Posttransplant follow-up should take the HEHE-LT score into account. Extrahepatic disease localization is reconfirmed not to be a contraindication for LT.

27 June 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
QLQuirino Lai
Quirino Lai
Alessandro VitaleAlessandro Vitale
Alessandro Vitale
SISamuele Iesari
Samuele Iesari
AFArmin Finkenstedt
Armin Finkenstedt
GMGianluca Mennini
Gianluca Mennini
OGon behalf of the European Hepatocellular Cancer Liver Transplant Study Group
on behalf of the European Hepatocellular Cancer Liver Transplant Study Group

1 December 2020 in JAMA Surgery
Verified
Journal Article
Closed access
PDF file
AAAlfonso W Avolio
Alfonso W Avolio
AFAntonio Franco
Antonio Franco
ASAndrea Schlegel
Andrea Schlegel
QLQuirino Lai
Quirino Lai
SMSonia Meli
Sonia Meli
PSPaolo De Simone
Paolo De Simone
Early allograft failure (EAF) is a major determinant of outcome after liver transplant (LT).1-6 Concerns have been raised on the acceptance of increased-risk donors (eg, elderly, highly comorbid, steatotic, donors after circulatory death [DCD]). The acceptance of individuals with such conditions might offset otherwise achieved survival improvements.7-10 In addition, the introduction of machine perfusion (MP) has led to the acceptance of grafts at higher risk of failure.11-15

10 July 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
UBUgo Boggi
Ugo Boggi
FVFabio Vistoli
Fabio Vistoli
AAAxel Andres
Axel Andres
HAHelmut P. Arbogast
Helmut P. Arbogast
LBLionel Badet
Lionel Badet
TBThierry Berney
Thierry Berney
The First World Consensus Conference on Pancreas Transplantation provided 49 jury deliberations regarding the impact of pancreas transplantation on the treatment of diabetic patients, and 110 experts’ recommendations for the practice of pancreas transplantation. The main message from this consensus conference is that both simultaneous pancreas-kidney transplantation (SPK) and pancreas transplantation alone can improve long-term patient survival, and all types of pancreas transplantation dramatically improve the quality of life of recipients. Pancreas transplantation may also improve the course of chronic complications of diabetes, depending on their severity. Therefore, the advantages of pancreas transplantation appear to clearly surpass potential disadvantages. Pancreas after kidney transplantation increases the risk of mortality only in the early period after transplantation, but is associated with improved life expectancy thereafter. Additionally, preemptive SPK, when compared to SPK performed in patients undergoing dialysis, appears to be associated with improved outcomes. Time on dialysis has negative prognostic implications in SPK recipients. Increased long-term survival, improvement in the course of diabetic complications, and amelioration of quality of life justify preferential allocation of kidney grafts to SPK recipients. Audience discussions and live voting are available online at the following URL address: http://mediaeventi.unipi.it/category/1st-world-consensus-conference-of-pancreas-transplantation/246.